novartis - Latest News, Analysis, Opinion

Stressing the surging healthcare inflation, Bishen, said that healthcare costs are out of control and it's not just a pain in the US but all around the globe. “The US is close to USD 5 trillion out of the USD 12 trillion in terms of the overall healthcare spending globally, which has gone from eight and half trillion in 2018 to 12 trillion in 2022.”

Novartis Plans To Take Drug Patent Case To US Supreme Court

Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals court ruling, the Swiss drugmaker said on Wednesday

Novartis: Scemblix Cleared In EU For Adults With Chronic Myeloid Leukemia

Novartis said on Monday its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia , offering a new treatment approach for patients with intolerance to other therapies

Pharma Major Novartis To Slash 8,000 Jobs Globally

Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating its pharmaceuticals and oncology business units and would lead to eliminating roles

Can We Afford This Wave?

Dr S S Mantha

Economy

People too are tired of all the restrictions, the loss of wages, loss of esteem and fatigue. More than 50% of the cases have originated in Maharashtra and its cities, defying normal logic.

Novartis Arthritis Drug Fails To Help COVID-19 Patients

The medicine, approved as Ilaris for juvenile arthritis and other conditions, also did not meet its key secondary endpoint of reducing COVID-19 mortality in a late-phase clinical trial

Novartis Arthritis Drug Fails To Help COVID-19 Patients

Healthcare Pharma

The medicine, approved as Ilaris for juvenile arthritis and other conditions, also did not meet its key secondary endpoint of reducing COVID-19 mortality in a late-phase clinical trial

Novartis Buys Vedere Bio, Whose Founders Helped Blind Mice See

Companies & Markets

Novartis is paying $150 million upfront for the U.S. biotechnology company, with the remainder in milestone payments for a total of $280 million.

Novartis Third-Quarter Core Net Income Rises To $3.47 Billion

The Basel-based company broadened its core operating income growth forecast to low double-digit to mid-teen percentage rate growth, from a low double-digit range previously, while net sales are expected to grow in the mid-single-digit percentage range.

Novartis Says Beovu Matched Rival Eylea In Visual Acuity In Eye Disease

"This data confirms our strong belief in Beovu as a potential therapy for DME patients," said Dirk Sauer, who leads Novartis Pharma Ophthalmology's drug development.

Roche Studies Ocrevus, Experimental Drug In MS As Novartis Moves In

Roche has started a late-stage clinical trial for its molecule fenebrutinib and is doing a clinical trial of higher-dose Ocrevus against relapsing MS and primary progressive MS.

Novartis Immuno-Oncology Drug Candidate Fails Skin Cancer Trial

Healthcare

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Novartis To Provide 'No Profit' COVID-19 Drugs To Low-Income Countries